0000899243-22-026486.txt : 20220721 0000899243-22-026486.hdr.sgml : 20220721 20220721164841 ACCESSION NUMBER: 0000899243-22-026486 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220719 FILED AS OF DATE: 20220721 DATE AS OF CHANGE: 20220721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALTSHULER DAVID CENTRAL INDEX KEY: 0001550395 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 221097572 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-19 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001550395 ALTSHULER DAVID C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP, Global Research and CSO Common Stock 2022-07-19 4 M 0 10427 187.53 A 46604 D Common Stock 2022-07-19 4 M 0 7338 155.57 A 53942 D Common Stock 2022-07-19 4 S 0 963 286.72 D 52979 D Common Stock 2022-07-19 4 S 0 4561 287.83 D 48418 D Common Stock 2022-07-19 4 S 0 5737 288.67 D 42681 D Common Stock 2022-07-19 4 S 0 6604 289.48 D 36077 D Stock Option (Right to Buy) 187.53 2022-07-19 4 M 0 10427 0.00 D 2029-02-05 Common Stock 10427 3911 D Stock Option (Right to Buy) 155.57 2022-07-19 4 M 0 7338 0.00 D 2028-02-05 Common Stock 7338 0 D Includes 100 shares previously purchased under the issuer's Employee Stock Purchase Plan. Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1. Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01). Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10). Open market sales reported on this line occurred at a weighted average price of $288.67 (range $288.11 to $289.09). Open market sales reported on this line occurred at a weighted average price of $289.48 (range $289.11 to $290.06). The option vests in 16 quarterly installments from 2/6/2019. Fully vested. /s/ Joy Liu, Attorney-in-Fact 2022-07-21